Grey matter and cognitive patterns in cognitive impaired subjects using CSF biomarker cut-offs

Journal of Alzheimer's Disease

Volumn 29, Issue 4, 2012, Pages 741-749

  Miralbell, Julia ^a   Spulber, Gabriela ^b,d   Hooshmand, Babak ^b   Besga, Ariadna ^c   Mataró, Maria ^a   Cedazo Minguez, Angel ^b   Kivipelto, Miia ^b,d   Wahlund, Lars Olof ^b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b KAROLINSKA INSTITUTE   (Sweden)

^c HOSPITAL TXAGORRITXU   (Spain)

^d UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Alzheimer's disease; CSF biomarkers; grey matter; MRI; voxel based morphometry

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; TAU PROTEIN;

ADULT; ALGORITHM; ALZHEIMER DISEASE; ARTICLE; BRAIN MAPPING; BRAIN SIZE; BRAIN TISSUE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; COGNITION; COGNITIVE DEFECT; FEMALE; GRAY MATTER; HUMAN; MALE; OCCIPITAL CORTEX; PARIETAL CORTEX; PREFRONTAL CORTEX; PRIORITY JOURNAL; SWEDEN; TEMPORAL CORTEX;

EID: 84860185726     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2012-111553     Document Type: Article

References (49)

1. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Delacourte A, Frisoni G, Fox NC, Galasko D, Gauthier S, Hampel H, Jicha G, Meguro K, O'Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Sarazin M, de Souza L, Stern Y, Visser PJ, Scheltens P (2011) Revising the definition of Alzheimer's disease: A new lexicon. Lancet Neurol 9, 1118-1127.
2. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, O'Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P (2007) Research criteria for the diagnosis of Alzheimer's disease: Revising the NINCDS-ADRDA criteria. Lancet Neurol 6, 734-746. (Pubitemid 47058377)
3. Cedazo-Minguez A, Winblad B (2010) Biomarkers for Alzheimer's disease and other forms of dementia: Clinical needs, limitations and future aspects. Exp Gerontol 45, 5-14.
4. Schoonenboom NSM, van der Flier WM, Blankenstein MA, Bouwman FH, Van Kamp GJ, Barkhof F, Scheltens P (2008) CSF and MRI markers independently contribute to the diagnosis of Alzheimer's disease. Neurobiol Aging 29, 669-675. (Pubitemid 351400823)
5. Strozyk D, Blennow K, White LR, Launer LJ (2003) CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology 60, 652-656. (Pubitemid 36246085)
6. Furst AJ, Rabinovici GD, Rostomian AH, Steed T, Alkalay A, Racine C, Miller BL, Jagust WJ (2012) Cognition, glucose metabolism and amyloid burden in Alzheimer's disease. Neurobiol Aging 33, 215-225.
7. Blennow K, Hampel H (2003) CSF markers for incipient Alzheimer's disease. Lancet Neurol 2, 605-613. (Pubitemid 37162569)
8. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter W, Lee VM, Tro-janowski JQ (2009) Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 65, 403-413.
9. Jack CRJ, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ (2010) Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 9, 119-128.
10. Vemuri P, Wiste HJ, Weigand SD, Shaw LM, Trojanowski JQ, Weiner MW, Knopman DS, Petersen RC, Jack CRJ (2009) MRI and CSF biomarkers in normal, MCI, and AD subjects: Predicting future clinical change. Neurology 73, 294-301.
11. Brys M, Glodzik L, Mosconi L, Switalski R, De Santi S, Pirraglia E, Rich K, Kim BC, Mehta P, Zinkowski R, Pratico D, Wallin A, Zetterberg H, Tsui WH, Rusinek H, Blennow K, de Leon MJ (2009) Magnetic resonance imaging improves cerebrospinalfluid biomarkersinthe early detection of Alzheimer's disease. J Alzheimers Dis 16, 351-362.
12. de Souza LC, Chupin M, Lamari F, Jardel C, Leclercq D, Colliot O, Lehéricy S, Dubois B, Sarazin M (2011) CSF tau markers are correlated with hippocampal volume in Alzheimer's disease. Neurobiol Aging, doi: 10. 1016/j. neurobiolaging. 2011. 02. 022.
13. Fagan AM, Head D, Shah AR, Marcus D, Mintun M, Morris JC, Holtzman DM (2009) Decreased cerebrospinal fluid Abeta (42) correlates with brain atrophy in cognitively normal elderly. Ann Neurol 65, 176-183.
14. Henneman WJP, Vrenken H, Barnes J, Sluimer IC, Verwey NA, Blankenstein MA, Klein M, Fox NC, Scheltens P, Barkhof F, van der Flier WM (2009) Baseline CSF p-tau levels independently predict progression of hippocampal atrophy in Alzheimer disease. Neurology 73, 935-940.
15. Herukka S, Pennanen C, Soininen H, Pirttilä T (2008) CSF Abeta42, tau and phosphorylated tau correlate with medial temporal lobe atrophy. J Alzheimers Dis 14, 51-57. (Pubitemid 352039012)
16. Rami L, Solé-Padullés C, Fortea J, Bosch B, Lladó A, Antonell A, Olives J, Castellv́i M, Bartres-Faz D, Sánchez-Valle R, Luis Molinuevo J (2012) Applying the new research diagnostic criteria: MRIfindings and neuropsychological correlations of prodromal AD. Int J Geriatr Psychiatry 27, 127-134.
17. Vemuri P, Wiste HJ, Weigand SD, Knopman DS, Trojanowski JQ, Shaw LM, Bernstein MA, Aisen PS, Weiner M, Petersen RC, Jack CRJ (2010) Serial MRI and CSF biomarkers in normal aging, MCI, and AD. Neurology 75, 143-151.
18. Lin Y, Cheng J, Yao Y, Juo, Lo Y, Lin C, Ger L, Lu P (2009) Increased total TAU but not amyloid-beta (42) in cere-brospinalfluid correlates with short-term memory impairment in Alzheimer's disease. J Alzheimers Dis 18, 907-918.
19. Glodzik L, Mosconi L, Tsui W, de Santi S, Zinkowski R, Pirraglia E, Rich KE, McHugh P, Li Y, Williams S, Ali F, Zetterberg H, Blennow K, Mehta P, de Leon MJ (2011) Alzheimer's disease markers, hypertension, and gray matter damage in normal elderly. Neurobiol biol Aging, doi: 10. 1016/j. neurobiolaging. 2011. 02. 012.
20. Fjell AM, Walhovd KB, Amlien I, Bjørnerud A, Reinvang I, Gjerstad L, Cappelen T, Willoch F, Due-Tønnessen P, Grambaite R, Skinningsrud A, Stenset V, Fladby T (2008) Morphometric changes in the episodic memory network and tau pathologic features correlate with memory performance in patients with mild cognitive impairment. AJNR Am J Neu-roradiol 29, 1183-1189. (Pubitemid 351954891)
21. Stenset V, Bjørnerud A, Fjell AM, Walhovd KB, Hofoss D, Due-Tønnessen P, Gjerstad L, Fladby T (2011) Cingulum fiber diffusivity and CSF T-tau in patients with subjective and mild cognitive impairment. Neurobiol Aging 32, 581-589.
22. Wahlund L, Blennow K (2003) Cerebrospinal fluid biomark-ers for disease stage and intensity in cognitively impaired patients. Neurosci Lett 339, 99-102. (Pubitemid 36254786)
23. Andreasen N, Hesse C, Davidsson P, Minthon L, Wallin A, Winblad B, Vanderstichele H, Vanmechelen E, Blennow K (1999) Cerebrospinal fluid beta-amyloid (1-42) in Alzheimer disease: Differences between early-and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol 56, 673-680. (Pubitemid 29266465)
24. Andersson C, Blennow K, Johansson S, Almkvist O, Engfeldt P, Lindau M, Eriksdotter-Jönhagen M (2007) Differential CSF biomarker levels in APOE-epsilon4-positive and-negative patients with memory impairment. Dement Geriatr Cogn Dis-ord 23, 87-95.
25. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: Report ofthe NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944. (Pubitemid 14076461)
26. Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund L-O, Nordberg A, Bäckman L, Albert M, Almkvist O, Arai H, Basun H, Blennow K, de Leon M, Decarli C, Erk-injuntti T, Giacobioni E, Graff C, Hardy J, Jack C, Jorm C, Ritchie K, Van Duijn C, Visser P, Petersen RC (2004) Mild cognitive impairment-beyond controversies, towards a consensus: Report of the International Working Group on Mild Cognitive Impairment. J Int Med 256, 240-246. (Pubitemid 39222993)
27. Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E (1995) Tau protein in cerebrospinal fluid: A biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol 26, 231-245. (Pubitemid 26002016)
28. Vanmechelen E, Vanderstichele H, Davidsson P, Van Ker-schaver E, Van Der Perre B, Sjögren M, Andreasen N, Blennow K (2000) Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: A sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett 285, 49-52. (Pubitemid 30224621)
29. Sjögren M, Vanderstichele H, Agren H, Zachrisson O, Edsbagge M, Wikkelsø C, Skoog I, Wallin A, Wahlund LO, Marcusson J, Nägga K, Andreasen N, Davidsson P, Vanmechelen E, Blennow K (2001) Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: Establishment of reference values. Clin Chem 47, 1776-1781. (Pubitemid 32881189)
30. Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka S, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek M, Tsolaki M, Mulugeta E, Rosén E, Aarsland D, Visser PJ, Schröder J, Marcusson J, de Leon M, Hampel H, Scheltens P, Pirttilä T, Wallin A, Jönhagen ME, Minthon L, Winblad B, Blennow K (2009) CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 302, 385-393.
31. Folstein MF, Folstein SE, McHugh PR (1975) "Mini-mental state. " A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12, 189-198.
32. Reisberg B, Ferris SH, de Leon MJ, Crook T (1982) The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry 139, 1136-1139 (Pubitemid 12051593)
33. Smith SM (2002) Fast robust automated brain extraction. Hum Brain Mapp 17, 143-155. (Pubitemid 35253488)
34. Smith SM, Jenkinson M, Woolrich MW, Beckmann CF, Behrens TEJ, Johansen-Berg H, Bannister PR, De Luca M, Drobnjak I, Flitney DE, Niazy RK, Saunders J, Vickers J, Zhang Y, De Stefano N, Brady JM, Matthews PM (2004) Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage 23 (Suppl 1), S208-S219. (Pubitemid 39421720)
35. Ashburner J, Friston KJ (2000) Voxel-based morphometry-the methods. Neuroimage 11, 805-821.
36. Wishart HA, Saykin AJ, McAllister TW, Rabin LA, McDonald BC, Flashman LA, Roth RM, Mamourian AC, Tsongalis GJ, Rhodes CH (2006) Regional brain atrophy in cognitively intact adults with a single APOE epsilon4 allele. Neurology 67, 1221-1224. (Pubitemid 44563831)
37. Kim S, Swaminathan S, Shen L, Risacher SL, Nho K, Foroud T, Shaw LM, Trojanowski JQ, Potkin SG, Huentelman MJ, Craig DW, DeChairo BM, Aisen PS, Petersen RC, Weiner MW, Saykin AJ (2011) Genome-wide association study of CSF biomarkers Abeta1-42, t-tau, and p-tau181p in the ADNI cohort. Neurology 76, 69-79.
38. Morris JC, Roe CM, Xiong C, Fagan AM, Goate AM, Holtz-man DM, Mintun MA (2010) APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol 67, 122-131.
39. Smith SM, Jenkinson M, Johansen-Berg H, Rueckert D, Nichols TE, Mackay CE, Watkins KE, Ciccarelli O, Cader MZ, Matthews PM, Behrens TEJ (2006) Tract-based spatial statistics: Voxelwise analysis of multi-subject diffusion data. Neuroimage 31, 1487-1505.
40. Thomann PA, Kaiser E, Schönknecht P, Pantel J, Essig M, Schröder J (2009) Association oftotal tau and phosphorylated tau 181 protein levelsin cerebrospinal fluid with cerebral atrophy in mild cognitive impairment and Alzheimer disease. J Psychiatry Neurosci 34, 136-142.
41. Solé-Padullés C, Lladó A, Bartrés-Faz D, Fortea J, Sánchez-Valle R, Bosch B, Antonell A, Molinuevo JL, Rami L (2011) Association between cerebrospinal fluid tau and brain atrophy is not related to clinical severity in the Alzheimer's disease continuum. Psychiatry Res 192, 140-146.
42. Grambaite R, Stenset V, Reinvang I, Walhovd KB, Fjell AM, Fladby T (2010) White matter diffusivity predicts memory in patients with subjective and mild cognitive impairment and normal CSF total tau levels. J Int Neuropsychol Soc 16, 58-69.
43. Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K (2006) Staging of Alzheimer disease-associated neurofibrillarypathology using paraffin sections and immuno-cytochemistry. Acta Neuropathol 112, 389-404. (Pubitemid 44469160)
44. Tapiola T, Alafuzoff I, Herukka S, Parkkinen L, Hartikainen P, Soininen H, Pirttilä T (2009) Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol 66, 382-389.
45. Josephs KA, Whitwell JL, Ahmed Z, Shiung MM, Weigand SD, Knopman DS, Boeve BF, Parisi JE, Petersen RC, Dickson DW, Jack CRJ (2008) Beta-amyloid burden is not associated with rates of brain atrophy. Ann Neurol 63, 204-212. (Pubitemid 351355299)
46. Whitwell JL, Josephs KA, Murray ME, Kantarci K, Przy-belski SA, Weigand SD, Vemuri P, Senjem ML, Parisi JE, Knopman DS, Boeve BF, Petersen RC, Dickson DW, Jack CRJ (2008) MRI correlates of neurofibrillary tangle pathology atautopsy:Avoxel-based morphometry study. Neurology 71, 743-749.
47. McDonald CR, McEvoy LK, Gharapetian L, Fennema-Notestine C, Hagler DJJ, Holland D, Koyama A, Brewer JB, Dale AM (2009) Regional rates of neocortical atrophy from normal aging to early Alzheimer disease. Neurology 73, 457-465.
48. Schoonenboom SNM, Visser PJ, Mulder C, Lindeboom J, Van Elk EJ, Van Kamp GJ, Scheltens PH (2005) Biomarker profiles and their relation to clinical variablesin mild cognitive impairment. Neurocase 11, 8-13. (Pubitemid 40372855)
49. Tosun D, Schuff N, Truran-Sacrey D, Shaw LM, Trojanowski JQ, Aisen P, Peterson R, Weiner MW (2010) Relations between brain tissue loss, CSF biomarkers, and the ApoE genetic profile: A longitudinal MRI study. Neurobiol Aging 31, 1340-1354.